| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.81 [0.60, 1.10] | | < 1 | | 78% | 2 studies (2/-) | 90.9 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.66 [0.55, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.68 [0.57, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.70 [0.57, 0.86] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 1.80 [1.31, 2.48] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.51 [0.27, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.02 [0.76, 1.37] | | < 1 | | 0% | 1 study (1/-) | 44.6 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 2.19 [1.17, 4.11] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.43 [0.97, 2.10] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.14 [1.32, 3.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.73 [1.33, 2.25] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.70 [1.26, 2.30] | | < 1 | | 10% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.69 [0.14, 3.33] | | < 1 | | 96% | 2 studies (2/-) | 67.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.89 [0.35, 2.28] | | < 1 | | 94% | 2 studies (2/-) | 59.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.39 [0.59, 3.30] | | < 1 | | 0% | 2 studies (2/-) | 22.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 2.15 [1.01, 4.58] | | < 1 | | 80% | 2 studies (2/-) | 2.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 3.26 [2.13, 4.99] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 6.74 [0.82, 55.04] | | < 1 | | 0% | 2 studies (2/-) | 3.8 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.09 [0.00, 2.47] | | < 1 | | 82% | 2 studies (2/-) | 92.0 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.23 [0.05, 1.07] | | < 1 | | 22% | 2 studies (2/-) | 96.9 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 11.58 [1.50, 89.46] | | < 1 | | 0% | 2 studies (2/-) | 1.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.65 [0.05, 8.42] | | < 1 | | 0% | 2 studies (2/-) | 63.0 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.96 [0.36, 2.58] | | < 1 | | 0% | 2 studies (2/-) | 53.1 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 5.59 [1.92, 16.29] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 1.81 [0.52, 6.25] | | < 1 | | 46% | 2 studies (2/-) | 17.5 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.38 [0.60, 3.15] | | < 1 | | 0% | 1 study (1/-) | 22.3 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 13.52 [0.76, 239.13] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 3.58 [0.38, 33.87] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.46 [0.47, 12.75] | | < 1 | | 0% | 1 study (1/-) | 14.3 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 7.55 [2.24, 25.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 4.93 [0.57, 42.41] | | < 1 | | 0% | 1 study (1/-) | 7.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.58 [0.06, 5.69] | | < 1 | | 69% | 2 studies (2/-) | 68.0 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.12 [0.00, 6.19] | | < 1 | | 87% | 2 studies (2/-) | 85.0 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 7.74 [0.96, 62.17] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 3.00 [0.28, 32.52] | | < 1 | | 0% | 2 studies (2/-) | 18.4 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 3.25 [0.27, 38.64] | | < 1 | | 35% | 2 studies (2/-) | 17.7 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.21 [0.01, 8.21] | | < 1 | | 84% | 2 studies (2/-) | 79.4 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.38 [0.02, 5.93] | | < 1 | | 69% | 2 studies (2/-) | 75.3 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.12 [0.05, 0.28] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.86 [0.36, 2.05] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.63 [0.10, 3.80] | | < 1 | | 0% | 1 study (1/-) | 69.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.90 [0.17, 21.07] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.43 [0.40, 5.11] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.12 [0.73, 6.17] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.11 [0.37, 3.33] | | < 1 | | 0% | 1 study (1/-) | 42.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.31 [0.52, 3.31] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.63 [0.18, 2.25] | | < 1 | | 0% | 1 study (1/-) | 76.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.95 [0.06, 15.23] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.13 [0.02, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.3 % | NA | not evaluable | | non important | - |
